
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics Inc. demonstrates a positive financial outlook, evidenced by an adjusted gross margin of 46.8%, which reflects a year-over-year increase of 150 basis points, and an adjusted EBITDA margin of 4.2%, up 200 basis points, surpassing consensus expectations. Additionally, revenue per test increased by 2.7% to $459 in the fourth quarter of 2024, supported by improvements in pricing, revenue cycle management (RCM), and a favorable mix of next-generation sequencing (NGS) testing. Furthermore, NGS testing revenue surged by 18% in the first quarter of 2025, highlighting significant growth in a crucial segment of its service offerings.
Bears say
NeoGenomics Inc. faces significant headwinds due to disappointing non-clinical sales, which totaled $18.3 million, falling short of the consensus estimate of $20.9 million and representing a 15.6% decline compared to previous growth rates. The company is also exposed to potential risks including negative reimbursement changes, patent litigation challenges, and increased competition, which could further erode market share. Additionally, greater than expected reinvestment demands may result in weaker EBITDA margins, compounding the challenges faced by the company in its current financial landscape.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares